Wilmington Savings Fund Society FSB Has $601,000 Position in Edwards Lifesciences Co. (NYSE:EW)

Wilmington Savings Fund Society FSB raised its stake in Edwards Lifesciences Co. (NYSE:EW) by 147.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,106 shares of the medical research company’s stock after acquiring an additional 5,420 shares during the period. Wilmington Savings Fund Society FSB’s holdings in Edwards Lifesciences were worth $601,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of EW. Stableford Capital II LLC grew its stake in Edwards Lifesciences by 2.7% during the second quarter. Stableford Capital II LLC now owns 6,104 shares of the medical research company’s stock worth $533,000 after buying an additional 159 shares in the last quarter. Purus Wealth Management LLC boosted its position in shares of Edwards Lifesciences by 5.2% during the 2nd quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company’s stock worth $297,000 after acquiring an additional 160 shares in the last quarter. Busey Bank increased its stake in Edwards Lifesciences by 1.9% in the second quarter. Busey Bank now owns 8,838 shares of the medical research company’s stock valued at $816,000 after acquiring an additional 165 shares during the last quarter. Commerzbank Aktiengesellschaft FI raised its position in Edwards Lifesciences by 7.4% during the second quarter. Commerzbank Aktiengesellschaft FI now owns 2,415 shares of the medical research company’s stock valued at $224,000 after purchasing an additional 166 shares in the last quarter. Finally, JFS Wealth Advisors LLC lifted its stake in Edwards Lifesciences by 31.1% during the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after purchasing an additional 166 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 35,000 shares of company stock worth $2,323,150. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Down 0.9 %

EW opened at $73.32 on Monday. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a fifty day moving average of $69.42 and a 200-day moving average of $73.90. The stock has a market cap of $43.24 billion, a PE ratio of 10.58, a price-to-earnings-growth ratio of 3.63 and a beta of 1.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period last year, the company posted $0.59 EPS. The business’s quarterly revenue was up 8.9% on a year-over-year basis. On average, sell-side analysts predict that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on EW. Stifel Nicolaus lifted their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a research note on Thursday, December 5th. Jefferies Financial Group cut Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their target price for the company from $85.00 to $70.00 in a research report on Wednesday, September 18th. Sanford C. Bernstein raised shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Oppenheimer reaffirmed an “outperform” rating and set a $90.00 price target on shares of Edwards Lifesciences in a report on Thursday, September 12th. Finally, Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Seventeen equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $78.65.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.